(1) 新药临床前药效学研究
(2) 生化药理学研究
(3) 神经药理学研究

1、科研项目
（1）国家自然科学基金面上项目，肝脏枯否细胞FcγRIIB受体介导慢性非可控炎症促进肝癌起始细胞形成的信号网络研究，2017-01 至 2020-12，51万元，已结题，主持
（2）国家自然科学基金项目，Y161003-1 脑、肠轴调控巨噬细胞介导非可控性炎症促进结肠癌起始细胞形成的网络关键节点研究，2016至 2019，20万，已结题，参加
（3）科技部重大专项(新药创制)，新型长效降血糖研究（Y151021-1），2015 至 2017，15万元，已结题，参加
（4）国家自然科学基金面上项目，Y141054-1，FcγRIIB受体调控肿瘤转移的作用及机制研究，2014至 2015， 20万，已结题，参加
（5）科技部重大专项，中药一类抗呼吸道病毒新药黄芩素片的临床前研究（Y131033-5），2013 至 2015，10万元，已结题，参加
（6）国家科技部，蛋白质药物的规模化制备技术（Y111004） 2011 至 2014，6万元，已结题，参加
（7）多项企业合作项目

1.Wu, H.; Li, Y.; Shi, G.; Du, S.; Wang, X.; Ye, W.; Zhang, Z.; Chu, Y.; Ma, S.; Wang, D.; Li, Y.; Chen, Z.; Birnbaumer, L.; Wang, Z.*; Yang, Y.*, Hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti-programmed cell death protein-1 therapy. Hepatology 2022. doi.org/10.1002/hep.32316. Online ahead of print. (IF:17.292)
2.Duan, JJ;Wang, Z;Duan, R;Yang, CXH;Zhao, RL;Feng, Q;Qin, YY;Jiang, JW;Gu, SY;Lv, KY;Zhang, LB;He, BX;Birnbaumer, L;Yang, S;Chen, Z;Yang, Y. Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice. HEPATOLOGY. 2022;75;140-153. (IF=17.425)
3.Shi, GJ;Zhang, ZX;Ma, SQ;Li, Y;Du, SJ;Chu, Y;Li, Y;Tang, XY;Yang, Y;Chen, Z*;Wang, Z*;Wu, HX* .Hepatic interferon regulatory factor 8 expression mediates liver ischemia/reperfusion injury in mice. Biochemical Pharmacology. 2021;192; 114728. (IF=5.858)
4.Shufang Zheng, Jiaping Ni, Ying Li, Mingying Lu, Yuchen Yao, Haixin Guo, Meng Jiao, Tianle Jin, Haoying Zhang, Ansheng Yuan, Zhuo Wang, Yong Yang, Zhen Chen,*, Hongxi Wu,*, Weiwei Hu*. 2-Methoxyestradiol synergizes with Erlotinib to suppress hepatocellular carcinoma by disrupting the LAGL2-EGFR-HIF-1/2α signaling loop. Pharmacological Research 2021;169: 105685. (IF: 7.658)
5.Wu, H.; You, L.; Li, Y.; Zhao, Z.; Shi, G.; Chen, Z.; Wang, Z.; Li, X.; Du, S.; Ye, W.; Gao, X.; Duan, J.; Cheng, Y.; Tao, W.; Bian, J.; Zhou, J. R.; Zhu, Q.; Yang, Y., Loss of a Negative Feedback Loop between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance. Cancer Res 2020, 80 (13), 2927-2939. (IF: 12.701)
6.Yue, SW;Xue, N;Li, HL;Chen, Z;Huang, BS*;Wang, X*. Isomangiferin Attenuates Renal Injury in Diabetic Mice via Inhibiting Inflammation. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy. 2020;  13: 4273-4280 (IF: 2.842)
7.Yue, SW;Xue, N;Li, HL;Huang, BS;Chen, Z;Wang, X*. Hepatoprotective Effect of Apigenin Against Liver Injury via the Non-canonical NF-κB Pathway In Vivo and In Vitro. Inflammation. 2020; 43 (5): 1634-1648 (IF: 3.212)
8.Li, JN; Lu, Y;Wang, DW; Quan, F; Chen, X; Sun, R; Zhao, S; Yang, ZS; Tao, WY; Ding, D; Gao, XH; Cao, QH; Zhao, DD; Qi, R; Chen, C; He, LH; Hu, KY; Chen, Z; Yang,Y; Luo, Y. Schisandrin B prevents ulcerative colitis and colitis-associated-cancer by activating focal adhesion kinase and influence on gut microbiota in an in vivo and in vitro model. EUROPEAN JOURNAL OF PHARMACOLOGY.2019; 854:9–21 (IF: 3.17)
9.Shi, GJ;Li, Y;Cao, QH;Wu, HX;Tang, XY;Gao, XH;Yu, JQ;Chen, Z;Yang, Y. In vitro and in vivo evidence that quercetin protects against diabetes and its complications: A systematic review of the literature. BIOMEDICINE & PHARMACOTHERAPY.2019;109: 1085-1099. (IF: 3.743)
10.Guang-Jiang Shi, Jie Zheng, Xiao-Xu Han, Ya-Ping Jiang, Zhi-Mei Li, Jing Wu, Qing Chang, Yang Niu, Tao Sun, Yu-Xiang Li*, Zhen Chen *& Jian-Qiang Yu*.Lycium barbarum polysaccharide attenuates diabetic testicular dysfunction via inhibition of the PI3K/Akt pathway-mediated abnormal autophagy in male mice. Cell and Tissue Research volume 2018; 374:653–666 (IF: 3.043)